echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Trail, a new biological anticancer drug under humanwell pharmaceutical, obtained clinical approval

    Trail, a new biological anticancer drug under humanwell pharmaceutical, obtained clinical approval

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the recombinant human tumor necrosis factor related apoptosis inducing ligand (TRAIL) applied by Shenzhen Xinpeng Bioengineering Co., Ltd., a subsidiary of humanwell Pharmaceutical Group, has successfully obtained the phase II and phase III clinical trial approval (approval No 2015l01865) issued by the State Food and Drug Administration (CFDA)   Trail is a new member of tumor necrosis factor superfamily (TNF) It can selectively induce apoptosis of tumor cells without obvious damage to normal tissues by binding with death receptors on the cell surface to initiate apoptosis signal transduction It is a research hotspot of anti-tumor drugs in the field of cell apoptosis It will be incomparable to the chemotherapeutic drugs that are used in clinic Once developed successfully, it will create huge social and economic benefits As a high-tech enterprise focusing on the research and development and production of genetically engineered drugs, Xinpeng biology continues to carry out technological innovation in protein recombinant drugs in accordance with the enterprise spirit of "striving, seeking truth and innovation" As an anti-tumor national first-class new drug with independent intellectual property rights, trail is a major scientific and technological special project for new drug creation during the 12th Five Year Plan period, and has obtained key support from the state, provinces and cities It has obtained two national authorized invention patent certificates For the first time, trail has established peptide fragment recombination technology to express natural trail extracellular region mutation at home and abroad, and successfully expressed soluble recombinant TRAIL in prokaryotic system In phase I clinical trial, 29 patients with advanced cancer were enrolled, and single and multiple dose climbing tests were carried out The results show that trail is well tolerated and has a certain anti-tumor effect However, due to the short treatment time and small number of cases, the exact anti-tumor effect and side effects will be further observed in phase II and III clinical studies I believe that the successful development of trail will become a heavy bomb in the field of anti-tumor, and help Xinpeng biology become the leader of biotechnology industry About Xinpeng biology, Shenzhen Xinpeng Bioengineering Co., Ltd (hereinafter referred to as Xinpeng Biology) is a high-tech biotechnology enterprise approved by the former State Science and Technology Commission and established in Shenzhen in 1992 It is one of the earliest enterprises engaged in biological drug research and industrialization in China The company is a wholly-owned subsidiary of Wuhan humanwell Pharmaceutical Group Co., Ltd located in Shenzhen high tech park, with a registered capital of 100 million yuan     The company has long been committed to the R & D, production and sales of biotechnological drugs, established Shenzhen modern biotechnological drug preparation engineering research and development center, with advanced biotechnological drug R & D and production platform and a group of technicians and managers engaged in the R & D and production of biotechnological drugs for a long time, and successively worked with Changchun Institute of biological products and Peking University Medical Science The Institute, Institute of Virology of Chinese Academy of preventive medicine and basic Institute of Chinese Academy of medical sciences have cooperated to undertake a number of national "863" projects Four products have obtained new drug certificates and production approval documents, among which recombinant human interleukin-2 and recombinant human interferon α - 2b have been technically transferred Recombinant human granulocyte stimulating factor injection and recombinant human erythropoietin injection are produced by the company Sale      
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.